NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Zacks Research analyst K. Shah now forecasts that the company will post earnings of $4.69 per share for the quarter, down from […] ...

The findings, published Friday in JAMA Health Forum, suggest that blockbuster medications such as Novo Nordisk A/S’s Ozempic and Wegovy and Eli Lilly & Co.’s Mounjaro and Zepbound may actually be ...

as monotherapy or combined with abemaciclib, could provide an all-oral targeted therapy option after progression on endocrine therapy for patients with ER-positive, HER2-negative advanced breast ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable single-dose vials of the weight-loss drug Zepbound, streamlining access through a seamless platform. The ...

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound. Through Ro's platform, eligible patients can receive ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...